Core Viewpoint - Cardinal Health, Inc. is expected to report strong fourth-quarter fiscal 2025 results, driven by growth in the Pharmaceutical segment and recovery in the Medical segment, with adjusted EPS projected to increase by 10.3% year-over-year [1][2][8] Financial Performance - The company’s adjusted EPS for the last reported quarter was $2.35, exceeding the Zacks Consensus Estimate by 9.3%, with an average surprise of 10.3% over the last four quarters [1][2] - For the upcoming fourth quarter, the Zacks Consensus Estimate for revenues is $60.67 billion, reflecting a 1.3% increase from the prior year [7][8] Segment Analysis - The Pharmaceutical segment is anticipated to show robust performance, supported by strong volume trends in branded drugs and specialty physician practices, along with the expansion of the Outcomes platform [3][4] - The Medical segment is expected to continue its recovery, aided by improved global supply chain execution and stability in manufacturing, with modest sequential revenue growth anticipated [4][5] Cost Management - Operating discipline and cost-saving initiatives under the Medical Improvement Plan are expected to support margin stability, despite some offset from performance-based compensation and IT investments [5][6] Shareholder Value - Adjusted EPS is projected to benefit from segment-level profit growth, lower interest expenses, and share repurchases, with full-year adjusted EPS guidance maintained at $7.20-$7.35 [6][8] Market Performance - Cardinal Health's shares have gained 29.7% year-to-date, outperforming the Medical - Dental Supplies sector and the broader market [11][12] Valuation Metrics - The forward 12-month price-to-earnings (P/E) ratio for Cardinal Health is 16.5X, which is a premium compared to the industry average of 15.9X and its peers [16] Long-Term Initiatives - The company is investing in new distribution centers, including a facility in Fort Worth, TX, expected to enhance its distribution chain with advanced robotics and automation technologies [17][18]

Core Insights - Cardinal Health is expanding its Equity Rx program to improve access to prescription medications for those who cannot afford them, with a total investment of $5 million from the Cardinal Health Foundation [1][3][5] Group 1: Program Expansion - The Equity Rx program, initially launched in Ohio in 2023, aims to address the critical need for affordable medication access, especially for individuals with chronic conditions [2][3] - The program has successfully established partnerships with charitable clinics, allowing for the direct delivery of medications to patients during their primary care visits [3][6] - Equity Rx has expanded to 10 charitable clinics across Ohio, Pennsylvania, Tennessee, and Illinois, helping thousands of patients access free medications [3][6] Group 2: Statewide Drug Repository - Cardinal Health is launching Ohio's first statewide prescription drug repository to facilitate the donation and distribution of unused medications, which will help expand access to care [4][6] - The repository will be developed in partnership with the Ohio State Board of Pharmacy and is expected to be fully operational by 2027 [4][6] - The initiative aims to reduce waste from unexpired medications in nursing homes and long-term care facilities, ensuring they are redirected to those in need [4][6]

Core Insights - GeneDx Holdings Corp. reported a significant turnaround in Q2 2025 with adjusted diluted EPS of 50 cents, compared to a loss of 8 cents per share in the same period last year, exceeding estimates by 400% [1][8] - Total revenues for the quarter increased by 45.6% year over year to $102.7 million, surpassing the Zacks Consensus Estimate by 21.2% [2][9] - The company achieved a gross profit of $70.9 million, reflecting a 65.1% year-over-year increase, with gross margin expanding by 813 basis points to 69% [3][9] Revenue Performance - Exome and genome test revenues grew by 69% year over year, reaching $85.9 million [2][9] - The company crossed the $100 million revenue mark for the first time, marking a significant milestone [9] Expense and Profitability Metrics - Adjusted total operating expenses were $61.9 million, an increase of 15.7% year over year, leading to an operating profit of $9 million compared to an operating loss of $10.6 million in the previous year [4][9] - Selling and marketing expenses rose by 17.3% to $19.4 million, while general and administrative expenses increased by 5.3% to $27.4 million [3] Cash Position - At the end of Q2 2025, GeneDx had cash, cash equivalents, and marketable securities totaling $134.6 million, down from $159.2 million at the end of Q1 2025 [5] Future Outlook - The company raised its full-year 2025 sales guidance to a range of $400-$415 million from the previous $360-$375 million, with the Zacks Consensus Estimate currently at $371.3 million [6] - Adjusted net income for the year is expected to be positive, with earnings estimated at $1.13 per share [6] Strategic Developments - During the quarter, GeneDx advanced its growth strategy by acquiring Fabric Genomics, which supports a hybrid model for delivering genomic insights globally [10] - The company also expanded its commercial focus to include inborn errors of immunity as a new indication for its genetic testing [10]

Group 1 - The report provides a comprehensive analysis of the global and Chinese PVC feeding tube market, including growth trends, market size, and competitive landscape from 2019 to 2031 [1][3][4] - The PVC feeding tube market is segmented by product type and application, with specific growth trends highlighted for gastrointestinal and nasogastric tubes [3][4][5] - The report forecasts significant growth in the PVC feeding tube market, driven by increasing demand in hospitals and clinics [3][4][6] Group 2 - Global PVC feeding tube production capacity, output, and utilization rates are analyzed, showing trends from 2019 to 2031 [4][6][10] - The report details the supply and demand dynamics in the Chinese PVC feeding tube market, including production capacity and market demand projections [4][6][10] - Revenue and sales volume for both global and Chinese markets are projected, with specific figures provided for the years 2019, 2025, and 2031 [4][6][10] Group 3 - The competitive landscape of the PVC feeding tube market is examined, identifying key players and their market shares [5][6][10] - The report includes a SWOT analysis of Chinese PVC feeding tube companies, assessing their strengths, weaknesses, opportunities, and threats [6][10][12] - The supply chain dynamics of the PVC feeding tube industry are discussed, including procurement and production models [6][10][12] Group 4 - The report highlights the regulatory environment affecting the PVC feeding tube industry in China, including relevant policies and planning [6][10][12] - Future trends in the PVC feeding tube market are projected, emphasizing technological advancements and market drivers [6][10][12] - The report concludes with insights on the regional distribution of PVC feeding tube production and consumption in China [10][12][14]

Core Insights - Cardinal Health plans to release its fourth-quarter and year-end financial results for fiscal year 2025 on August 12, prior to the opening of trading on the New York Stock Exchange [1] - A webcast discussion of these results will begin at 8:30 a.m. Eastern on the same day [1] Access Information - The webcast and corresponding slide presentation can be accessed via Cardinal Health's Investor Relations page without the need for an access code [2] - Presentation slides and a replay of the webcast will be available on the Investor Relations page for 12 months [2] Company Overview - Cardinal Health is a distributor of pharmaceuticals and specialty products, a global manufacturer and distributor of medical and laboratory products, and a supplier of home-health and direct-to-patient products and services [3] - The company operates nuclear pharmacies and manufacturing facilities and provides performance and data solutions [3] - Cardinal Health emphasizes a customer-centric focus that drives continuous improvement and leads to innovative solutions that enhance people's lives [3]

Core Insights - Cardinal Health has launched the Cardinal Health™ One Voice Initiative aimed at providing financial assistance to state pharmacy associations to support independent pharmacists' advocacy efforts [1][2][3] - The initiative is part of Cardinal Health's ongoing commitment to advocate for independent pharmacies and enhance their influence in healthcare policy discussions [2][3] - Financial contributions will be made to state pharmacy associations, with support for additional states contingent on advocacy opportunities for the independent pharmacy community [3][4] Company Overview - Cardinal Health operates as a distributor of pharmaceuticals and specialty products, a global manufacturer and distributor of medical and laboratory products, and a provider of home-health and direct-to-patient products and services [5] - The company emphasizes a customer-centric focus that drives continuous improvement and innovation in solutions that enhance people's lives [5]

Core Viewpoint - Momentum investing focuses on following a stock's recent price trends, aiming to capitalize on established price movements for profitable trades [1] Company Overview: Cardinal Health (CAH) - Cardinal Health currently holds a Momentum Style Score of A, indicating strong momentum characteristics [2] - The company has a Zacks Rank of 2 (Buy), suggesting a favorable outlook compared to the market [3] Price Performance - Over the past week, CAH shares increased by 2.31%, outperforming the Zacks Medical - Dental Supplies industry, which rose by 1.28% [5] - In a longer timeframe, CAH shares have gained 33.67% over the past quarter and 71.85% over the last year, significantly outperforming the S&P 500's gains of 10.83% and 14.92%, respectively [6] Trading Volume - CAH's average 20-day trading volume is 2,322,982 shares, which serves as a bullish indicator when combined with rising stock prices [7] Earnings Outlook - In the past two months, 8 earnings estimates for CAH have been revised upwards, with no downward revisions, leading to an increase in the consensus estimate from $7.99 to $8.18 [9] - For the next fiscal year, 8 estimates have also moved upwards without any downward revisions [9] Conclusion - Considering the positive price trends, strong earnings outlook, and favorable momentum score, CAH is positioned as a solid momentum pick for investors [11]

Group 1: Company Performance - Cardinal Health (CAH) closed at $165.61, with a daily increase of +1.14%, outperforming the S&P 500's gain of 0.8% [1] - Over the past month, CAH shares increased by 6.94%, surpassing the Medical sector's gain of 3.12% and the S&P 500's gain of 5.12% [1] Group 2: Upcoming Financial Results - The upcoming EPS for Cardinal Health is projected at $2.02, indicating a 9.78% increase year-over-year [2] - The Zacks Consensus Estimate for revenue is $60.65 billion, reflecting a 1.31% increase from the previous year [2] Group 3: Full Year Projections - For the full year, earnings are projected at $8.18 per share, representing an increase of +8.63%, while revenue is expected to be $223.07 billion, a decrease of -1.72% from the prior year [3] Group 4: Analyst Estimates and Stock Performance - Changes in analyst estimates for Cardinal Health are important as they reflect short-term business trends and analysts' confidence in performance [4] - The Zacks Rank system, which incorporates estimate changes, indicates Cardinal Health holds a Zacks Rank of 2 (Buy) [6] Group 5: Valuation Metrics - Cardinal Health has a Forward P/E ratio of 20.03, which is higher than the industry average of 17.14 [7] - The company has a PEG ratio of 1.83, compared to the industry average PEG ratio of 1.7 [8] Group 6: Industry Context - The Medical - Dental Supplies industry, part of the Medical sector, holds a Zacks Industry Rank of 26, placing it in the top 11% of over 250 industries [9]

Core Insights - Zacks Premium offers tools for investors to enhance their stock market strategies, including daily updates, research reports, and stock screens [1] Zacks Style Scores - Zacks Style Scores are indicators that help investors select stocks likely to outperform the market in the next 30 days, rated from A to F based on value, growth, and momentum characteristics [2] - The Style Scores consist of four categories: Value Score, Growth Score, Momentum Score, and VGM Score [3][4][5][6] Value Score - The Value Score identifies attractive and discounted stocks using ratios like P/E, PEG, Price/Sales, and Price/Cash Flow [3] Growth Score - The Growth Score focuses on a company's financial strength and future outlook, analyzing projected and historical earnings, sales, and cash flow [4] Momentum Score - The Momentum Score assesses trends in stock price and earnings outlook, utilizing factors like one-week price change and monthly earnings estimate changes [5] VGM Score - The VGM Score combines all three Style Scores, providing a comprehensive indicator for selecting stocks with the best value, growth, and momentum [6] Zacks Rank - The Zacks Rank is a proprietary stock-rating model that leverages earnings estimate revisions to aid investors in portfolio creation [7] - Stocks rated 1 (Strong Buy) have historically produced an average annual return of +25.41% since 1988, significantly outperforming the S&P 500 [8] Stock Selection Strategy - To maximize returns, investors should focus on stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B [9] - Stocks with a 4 (Sell) or 5 (Strong Sell) rating, even with high Style Scores, are less favorable due to declining earnings forecasts [10] Company Spotlight: Cardinal Health - Cardinal Health is a global healthcare services and products distributor, operating in three segments: Pharmaceutical and Specialty Solutions, Global Medical Products and Distribution, and Other [11] - Cardinal Health holds a 3 (Hold) Zacks Rank and a VGM Score of B, with a Value Style Score of B, supported by a forward P/E ratio of 19.82 [12] - The company has seen upward revisions in earnings estimates, with the Zacks Consensus Estimate increasing by $0.20 to $8.14 per share, and an average earnings surprise of 10.3% [12]

Company Overview - Cardinal Health is a global healthcare services and products distributor, serving hospitals, healthcare providers, pharmacies, and manufacturers [11] - The company operates under three segments: Pharmaceutical and Specialty Solutions, Global Medical Products and Distribution (GMPD), and Other [11] Investment Insights - Cardinal Health has a Zacks Rank of 3 (Hold) and a VGM Score of B, indicating a moderate investment outlook [11] - The company has a Momentum Style Score of B, with shares increasing by 5.6% over the past four weeks [12] - Eight analysts have revised their earnings estimates upwards for fiscal 2025, with the Zacks Consensus Estimate rising by $0.18 to $8.12 per share [12] - Cardinal Health has an average earnings surprise of 10.3%, suggesting potential for positive performance [12]